Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A neuroscience biotech developing novel therapeutics for neurodegenerative and neuropsychiatric disorders.
NeuroscienceNeurodegenerative DiseasesPsychiatry
Technology Platform
A target discovery and validation platform integrating human genetics, proteomics, and advanced neuronal cell models to identify novel pathways in synaptic dysfunction and resilience.
Opportunities
Potential for breakthrough disease-modifying therapy in areas like Alzheimer's where current options are limited.
Risk Factors
High risk of clinical failure inherent in novel neuroscience targets and the difficulty of demonstrating efficacy in CNS trials.
Competitive Landscape
Operates in the crowded and high-failure-risk neuroscience sector, competing with large pharma giants and well-funded biotechs like Denali and Biogen.